TABLE 2

Antimicrobial susceptibility of the overall population of S. pneumoniae selected serotypes and resistance subsets based on CLSI breakpoints

Serotypea (total no. tested/%)Percentage susceptible/intermediate/resistantb
PenicillinCeftriaxoneErythromycinClindamycinLevofloxacinTetracyclineTMP-SMX
All (822)89.2/10.3/0.592.6/5.8/1.662.9/0.9/36.381.6/0.2/18.198.9/0.0/1.179.7/0.0/20.371.3/7.7/21.0
    19A (123/15.0)38.2/59.4/2.458.5/35.0/6.520.3/1.7/78.043.1/0.0/56.998.4/0.0/1.640.7/0.0/59.318.7/2.4/78.9
    3 (70/8.5)100.0/0.0/0.0100.0/0.0/0.092.9/2.8/4.395.7/0.0/4.398.6/0.0/1.487.1/0.0/12.9100.0/0.0/0.0
    35B (54/6.6)98.1/1.9/0.0100.0/0.0/0.037.0/0.0/63.096.3/0.0/3.7100.0/0.0/0.096.3/0.0/3.785.2/1.8/13.0
    6C/6D (53/6.4)100.0/0.0/0.098.1/1.9/0.052.8/1.9/45.398.1/0.0/1.996.2/0.0/3.898.1/0.0/1.950.9/0.0/49.1
    22A/22F (48/5.8)100.0/0.0/0.0100.0/0.0/0.085.4/0.0/14.695.8/0.0/4.297.9/0.0/2.1100.0/0.0/0.093.8/2.0/4.2
    11A/11D (47/5.7)100.0/0.0/0.0100.0/0.0/0.083.0/0.0/17.0100.0/0.0/0.097.9/0.0/2.1100.0/0.0/0.091.5/0.0/8.5
    15A/15F (45/5.5)100.0/0.0/0.0100.0/0.0/0.04.4/0.0/95.66.7/0.0/93.397.8/0.0/2.28.9/0.0/91.157.8/31.1/11.1
    7F (45/5.5)100.0/0.0/0.097.8/0.0/2.295.6/2.2/2.2100.0/0.0/0.0100.0/0.0/0.0100.0/0.0/0.097.8/0.0/2.2
    15B/15C (39/4.7)100.0/0.0/0.0100.0/0.0/0.056.4/0.0/43.694.9/0.0/5.1100.0/0.0/0.074.4/0.0/25.666.7/23.0/10.3
    19F (24/2.9)66.7/29.1/4.275.0/12.5/12.550.0/0.0/50.062.5/0.0/37.5100.0/0.0/0.054.2/0.0/45.850.0/4.2/45.8
    Otherc (274/33.3)98.5/1.5/0.099.2/0.4/0.480.3/0.4/19.392.7/0.7/6.699.6/0.0/0.492.7/0.0/7.381.8/12.4/5.8
MDRd (180/21.9)51.1/46.7/2.266.1/26.7/7.20.0/0.6/99.418.3/0.6/81.197/.2/0.0/2.812.8/0.0/87.222.2/15.0/62.8
Non-MDR (642/78.1)99.8/0.2/0.0100.0/0.0/0.080.5/0.1/18.599.4/0.2/0.499.4/0.0/0.698.4/0.0/1.685.0/5.6/9.3
  • a The 13-valent conjugate vaccine contains coverage against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

  • b This is breakpoint criteria according to 2016 CLSI standards. Breakpoints for penicillin (parenteral) nonmeningitis were applied (i.e., susceptible at ≤2 μg/ml, intermediate at 4 μg/ml, and resistant at ≥8 μg/ml). Erythromycin predicts susceptibility rates for azithromycin and clarithromycin.

  • c This category comprises 28 serotypes including those that are nontypeable.

  • d MDR, multidrug-resistant (i.e., isolates displaying a resistance phenotype to at least three drug classes). This includes the following serotypes/serogroups (no.): 19A (81), 15A/F (42), 15B/15C (10), 19F (11), nontypeable (7), 6C/6D (5), 23A (5), 3 (3), 9N/9L (3), 23F (3), 14 (3), 35B (2), 21 (1), 22F/22A (1), 6A (1), 7F (1), and 34 (1).